nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—ocular cancer	0.678	1	CbGbCtD
Bortezomib—Radiation injury—Dactinomycin—ocular cancer	0.00478	0.147	CcSEcCtD
Bortezomib—Venoocclusive liver disease—Dactinomycin—ocular cancer	0.00371	0.114	CcSEcCtD
Bortezomib—Fluid overload—Carboplatin—ocular cancer	0.00217	0.0668	CcSEcCtD
Bortezomib—PSMA1—epithelium—ocular cancer	0.00206	0.104	CbGeAlD
Bortezomib—PSMD1—eye—ocular cancer	0.00189	0.0956	CbGeAlD
Bortezomib—PSMD1—retina—ocular cancer	0.00188	0.0947	CbGeAlD
Bortezomib—PSMD2—eye—ocular cancer	0.00168	0.0846	CbGeAlD
Bortezomib—PSMD2—retina—ocular cancer	0.00166	0.0839	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—ocular cancer	0.00166	0.0835	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—ocular cancer	0.00159	0.0802	CbGeAlD
Bortezomib—Extravasation—Carboplatin—ocular cancer	0.00155	0.0476	CcSEcCtD
Bortezomib—Multi-organ failure—Dactinomycin—ocular cancer	0.00154	0.0473	CcSEcCtD
Bortezomib—PSMB1—eye—ocular cancer	0.00129	0.065	CbGeAlD
Bortezomib—PSMB2—eye—ocular cancer	0.00126	0.0634	CbGeAlD
Bortezomib—PSMB2—retina—ocular cancer	0.00124	0.0628	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—ocular cancer	0.00118	0.0596	CbGeAlD
Bortezomib—Cheilitis—Dactinomycin—ocular cancer	0.00118	0.0363	CcSEcCtD
Bortezomib—Phlebitis—Carboplatin—ocular cancer	0.00114	0.035	CcSEcCtD
Bortezomib—Ascites—Dactinomycin—ocular cancer	0.0011	0.034	CcSEcCtD
Bortezomib—PSMB1—lymphoid tissue—ocular cancer	0.000907	0.0458	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—ocular cancer	0.000885	0.0446	CbGeAlD
Bortezomib—Febrile neutropenia—Dactinomycin—ocular cancer	0.000834	0.0256	CcSEcCtD
Bortezomib—Hepatomegaly—Dactinomycin—ocular cancer	0.000709	0.0218	CcSEcCtD
Bortezomib—Hepatotoxicity—Dactinomycin—ocular cancer	0.00065	0.02	CcSEcCtD
Bortezomib—Coagulopathy—Dactinomycin—ocular cancer	0.000645	0.0198	CcSEcCtD
Bortezomib—Extravasation—Dactinomycin—ocular cancer	0.000575	0.0177	CcSEcCtD
Bortezomib—Hypocalcaemia—Dactinomycin—ocular cancer	0.000548	0.0169	CcSEcCtD
Bortezomib—Ulcer—Dactinomycin—ocular cancer	0.000531	0.0163	CcSEcCtD
Bortezomib—Infection—Carboplatin—ocular cancer	0.000479	0.0147	CcSEcCtD
Bortezomib—Oesophagitis—Dactinomycin—ocular cancer	0.000459	0.0141	CcSEcCtD
Bortezomib—Mouth ulceration—Dactinomycin—ocular cancer	0.000454	0.0139	CcSEcCtD
Bortezomib—Sepsis—Dactinomycin—ocular cancer	0.000435	0.0134	CcSEcCtD
Bortezomib—Phlebitis—Dactinomycin—ocular cancer	0.000423	0.013	CcSEcCtD
Bortezomib—Pain—Carboplatin—ocular cancer	0.000412	0.0127	CcSEcCtD
Bortezomib—Hepatic failure—Dactinomycin—ocular cancer	0.000405	0.0125	CcSEcCtD
Bortezomib—Body temperature increased—Carboplatin—ocular cancer	0.000381	0.0117	CcSEcCtD
Bortezomib—Lethargy—Dactinomycin—ocular cancer	0.000372	0.0114	CcSEcCtD
Bortezomib—CYP1A1—epithelium—ocular cancer	0.000338	0.0171	CbGeAlD
Bortezomib—Toxic epidermal necrolysis—Dactinomycin—ocular cancer	0.000328	0.0101	CcSEcCtD
Bortezomib—Dysphagia—Dactinomycin—ocular cancer	0.000315	0.00968	CcSEcCtD
Bortezomib—Pancytopenia—Dactinomycin—ocular cancer	0.000299	0.00919	CcSEcCtD
Bortezomib—PTGS1—epithelium—ocular cancer	0.000297	0.015	CbGeAlD
Bortezomib—Neutropenia—Dactinomycin—ocular cancer	0.000294	0.00905	CcSEcCtD
Bortezomib—Pneumonia—Dactinomycin—ocular cancer	0.000282	0.00868	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Dactinomycin—ocular cancer	0.000278	0.00856	CcSEcCtD
Bortezomib—Stomatitis—Dactinomycin—ocular cancer	0.000274	0.00841	CcSEcCtD
Bortezomib—Hepatitis—Dactinomycin—ocular cancer	0.000252	0.00775	CcSEcCtD
Bortezomib—Erythema multiforme—Dactinomycin—ocular cancer	0.000238	0.00733	CcSEcCtD
Bortezomib—Flushing—Dactinomycin—ocular cancer	0.000234	0.00719	CcSEcCtD
Bortezomib—Chills—Dactinomycin—ocular cancer	0.000226	0.00695	CcSEcCtD
Bortezomib—Erythema—Dactinomycin—ocular cancer	0.000219	0.00674	CcSEcCtD
Bortezomib—Ill-defined disorder—Dactinomycin—ocular cancer	0.000204	0.00626	CcSEcCtD
Bortezomib—Anaemia—Dactinomycin—ocular cancer	0.000203	0.00623	CcSEcCtD
Bortezomib—Malaise—Dactinomycin—ocular cancer	0.000198	0.00608	CcSEcCtD
Bortezomib—Leukopenia—Dactinomycin—ocular cancer	0.000196	0.00604	CcSEcCtD
Bortezomib—Myalgia—Dactinomycin—ocular cancer	0.000187	0.00574	CcSEcCtD
Bortezomib—Discomfort—Dactinomycin—ocular cancer	0.000185	0.00567	CcSEcCtD
Bortezomib—Oedema—Dactinomycin—ocular cancer	0.000179	0.0055	CcSEcCtD
Bortezomib—Infection—Dactinomycin—ocular cancer	0.000178	0.00547	CcSEcCtD
Bortezomib—Thrombocytopenia—Dactinomycin—ocular cancer	0.000175	0.00539	CcSEcCtD
Bortezomib—Anorexia—Dactinomycin—ocular cancer	0.000171	0.00525	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dactinomycin—ocular cancer	0.000163	0.00502	CcSEcCtD
Bortezomib—Decreased appetite—Dactinomycin—ocular cancer	0.000156	0.00479	CcSEcCtD
Bortezomib—Fatigue—Dactinomycin—ocular cancer	0.000154	0.00475	CcSEcCtD
Bortezomib—Pain—Dactinomycin—ocular cancer	0.000153	0.00471	CcSEcCtD
Bortezomib—Feeling abnormal—Dactinomycin—ocular cancer	0.000148	0.00454	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dactinomycin—ocular cancer	0.000146	0.0045	CcSEcCtD
Bortezomib—Body temperature increased—Dactinomycin—ocular cancer	0.000142	0.00435	CcSEcCtD
Bortezomib—Abdominal pain—Dactinomycin—ocular cancer	0.000142	0.00435	CcSEcCtD
Bortezomib—Hypersensitivity—Dactinomycin—ocular cancer	0.000132	0.00406	CcSEcCtD
Bortezomib—Asthenia—Dactinomycin—ocular cancer	0.000128	0.00395	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—ocular cancer	0.000122	0.00377	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—ocular cancer	0.000114	0.0035	CcSEcCtD
Bortezomib—Rash—Dactinomycin—ocular cancer	0.000113	0.00347	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—ocular cancer	0.000106	0.00327	CcSEcCtD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—ocular cancer	1.77e-05	6.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN2B—ocular cancer	1.75e-05	6.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN2B—ocular cancer	1.75e-05	6.48e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN2B—ocular cancer	1.75e-05	6.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN2B—ocular cancer	1.72e-05	6.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CDKN1B—ocular cancer	1.67e-05	6.18e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CDKN1A—ocular cancer	1.67e-05	6.18e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CDKN1B—ocular cancer	1.66e-05	6.15e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CDKN1A—ocular cancer	1.66e-05	6.15e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CDKN1B—ocular cancer	1.65e-05	6.13e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CDKN1A—ocular cancer	1.65e-05	6.12e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—E2F1—ocular cancer	1.6e-05	5.95e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—E2F1—ocular cancer	1.6e-05	5.95e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—E2F1—ocular cancer	1.6e-05	5.95e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSPH—ocular cancer	1.6e-05	5.94e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EP300—ocular cancer	1.59e-05	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—E2F1—ocular cancer	1.58e-05	5.86e-05	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—AKT1—ocular cancer	1.58e-05	5.86e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EP300—ocular cancer	1.58e-05	5.85e-05	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—AKT1—ocular cancer	1.57e-05	5.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EP300—ocular cancer	1.57e-05	5.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—AKT1—ocular cancer	1.56e-05	5.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—ocular cancer	1.55e-05	5.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—ocular cancer	1.55e-05	5.74e-05	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—ocular cancer	1.55e-05	5.74e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CDKN1A—ocular cancer	1.54e-05	5.71e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CDKN1A—ocular cancer	1.53e-05	5.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—ocular cancer	1.53e-05	5.66e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CDKN1A—ocular cancer	1.52e-05	5.65e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MDM2—ocular cancer	1.5e-05	5.56e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MDM2—ocular cancer	1.5e-05	5.56e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MDM2—ocular cancer	1.5e-05	5.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MDM2—ocular cancer	1.48e-05	5.48e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EP300—ocular cancer	1.46e-05	5.43e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EP300—ocular cancer	1.46e-05	5.4e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNA11—ocular cancer	1.45e-05	5.39e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EP300—ocular cancer	1.45e-05	5.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MDM2—ocular cancer	1.38e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MDM2—ocular cancer	1.38e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MDM2—ocular cancer	1.38e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MYC—ocular cancer	1.37e-05	5.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CDKN1B—ocular cancer	1.37e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CDKN1B—ocular cancer	1.37e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CDKN1B—ocular cancer	1.37e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—ocular cancer	1.37e-05	5.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MDM2—ocular cancer	1.36e-05	5.06e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—ocular cancer	1.36e-05	5.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—ocular cancer	1.36e-05	5.03e-05	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—ocular cancer	1.36e-05	5.03e-05	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—ocular cancer	1.36e-05	5.03e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNAQ—ocular cancer	1.35e-05	5.01e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CDKN1B—ocular cancer	1.35e-05	5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—ocular cancer	1.34e-05	4.96e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MDM2—ocular cancer	1.28e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MYC—ocular cancer	1.28e-05	4.73e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—ocular cancer	1.27e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MDM2—ocular cancer	1.27e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MYC—ocular cancer	1.27e-05	4.71e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—ocular cancer	1.27e-05	4.7e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MDM2—ocular cancer	1.27e-05	4.7e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MYC—ocular cancer	1.26e-05	4.69e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CDKN1B—ocular cancer	1.26e-05	4.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CDKN1B—ocular cancer	1.26e-05	4.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CDKN1B—ocular cancer	1.26e-05	4.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CDKN1A—ocular cancer	1.26e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CDKN1A—ocular cancer	1.26e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CDKN1A—ocular cancer	1.26e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—ocular cancer	1.26e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CDKN1B—ocular cancer	1.25e-05	4.62e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CDKN1A—ocular cancer	1.25e-05	4.62e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—EP300—ocular cancer	1.23e-05	4.55e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—EP300—ocular cancer	1.22e-05	4.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—EP300—ocular cancer	1.21e-05	4.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EP300—ocular cancer	1.2e-05	4.46e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EP300—ocular cancer	1.2e-05	4.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EP300—ocular cancer	1.2e-05	4.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—AKT1—ocular cancer	1.2e-05	4.44e-05	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—AKT1—ocular cancer	1.2e-05	4.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—AKT1—ocular cancer	1.2e-05	4.44e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EP300—ocular cancer	1.18e-05	4.39e-05	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—AKT1—ocular cancer	1.18e-05	4.38e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CDKN1B—ocular cancer	1.17e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CDKN1A—ocular cancer	1.17e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CDKN1A—ocular cancer	1.17e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CDKN1A—ocular cancer	1.17e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CDKN1B—ocular cancer	1.16e-05	4.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CDKN1B—ocular cancer	1.16e-05	4.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CDKN1A—ocular cancer	1.15e-05	4.26e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCND1—ocular cancer	1.11e-05	4.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EP300—ocular cancer	1.11e-05	4.12e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EP300—ocular cancer	1.11e-05	4.12e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EP300—ocular cancer	1.11e-05	4.12e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCND1—ocular cancer	1.11e-05	4.11e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCND1—ocular cancer	1.1e-05	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EP300—ocular cancer	1.09e-05	4.06e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.09e-05	4.05e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—ocular cancer	1.09e-05	4.03e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—ocular cancer	1.08e-05	4.01e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CDKN1A—ocular cancer	1.08e-05	4e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—ocular cancer	1.07e-05	3.99e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CDKN1A—ocular cancer	1.07e-05	3.98e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CDKN1A—ocular cancer	1.07e-05	3.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—ocular cancer	1.04e-05	3.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—ocular cancer	1.04e-05	3.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—ocular cancer	1.04e-05	3.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—ocular cancer	1.03e-05	3.81e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EP300—ocular cancer	1.03e-05	3.8e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNA11—ocular cancer	1.02e-05	3.8e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EP300—ocular cancer	1.02e-05	3.78e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EP300—ocular cancer	1.02e-05	3.77e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—ocular cancer	1e-05	3.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—ocular cancer	9.97e-06	3.7e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—ocular cancer	9.93e-06	3.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MDM2—ocular cancer	9.69e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MDM2—ocular cancer	9.69e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MDM2—ocular cancer	9.69e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—ocular cancer	9.67e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—ocular cancer	9.67e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—ocular cancer	9.67e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—ocular cancer	9.65e-06	3.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—ocular cancer	9.65e-06	3.58e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—ocular cancer	9.65e-06	3.58e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—ocular cancer	9.58e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MDM2—ocular cancer	9.55e-06	3.54e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—ocular cancer	9.54e-06	3.54e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—ocular cancer	9.53e-06	3.54e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—ocular cancer	9.53e-06	3.53e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNAQ—ocular cancer	9.52e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—ocular cancer	9.51e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—ocular cancer	9.49e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—ocular cancer	9.48e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—ocular cancer	9.44e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNA11—ocular cancer	9.39e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—ocular cancer	9.29e-06	3.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—ocular cancer	9.29e-06	3.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—ocular cancer	9.29e-06	3.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—ocular cancer	9.16e-06	3.4e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—ocular cancer	8.93e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—ocular cancer	8.91e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—ocular cancer	8.89e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—ocular cancer	8.87e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—ocular cancer	8.85e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1B—ocular cancer	8.85e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1B—ocular cancer	8.85e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1B—ocular cancer	8.85e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—ocular cancer	8.85e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—ocular cancer	8.83e-06	3.27e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—ocular cancer	8.81e-06	3.27e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—ocular cancer	8.76e-06	3.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNAQ—ocular cancer	8.73e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1B—ocular cancer	8.72e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—ocular cancer	8.44e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—ocular cancer	8.44e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—ocular cancer	8.44e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNA11—ocular cancer	8.38e-06	3.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—ocular cancer	8.32e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—ocular cancer	8.22e-06	3.05e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—ocular cancer	8.22e-06	3.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—ocular cancer	8.22e-06	3.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—ocular cancer	8.17e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—ocular cancer	8.17e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—ocular cancer	8.17e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—ocular cancer	8.11e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—ocular cancer	8.05e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNAQ—ocular cancer	7.79e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—ocular cancer	7.77e-06	2.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—ocular cancer	7.77e-06	2.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—ocular cancer	7.77e-06	2.88e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNA11—ocular cancer	7.71e-06	2.86e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	7.69e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—ocular cancer	7.66e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNA11—ocular cancer	7.64e-06	2.84e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—ocular cancer	7.59e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—ocular cancer	7.59e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—ocular cancer	7.59e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—ocular cancer	7.49e-06	2.78e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—ocular cancer	7.41e-06	2.75e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—ocular cancer	7.37e-06	2.74e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—ocular cancer	7.34e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—ocular cancer	7.34e-06	2.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—ocular cancer	7.3e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—ocular cancer	7.27e-06	2.7e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—ocular cancer	7.26e-06	2.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—ocular cancer	7.26e-06	2.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—ocular cancer	7.26e-06	2.69e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—ocular cancer	7.22e-06	2.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—ocular cancer	7.22e-06	2.68e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—ocular cancer	7.22e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNAQ—ocular cancer	7.17e-06	2.66e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—ocular cancer	7.16e-06	2.66e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—ocular cancer	7.12e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNAQ—ocular cancer	7.11e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—ocular cancer	7.05e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—ocular cancer	7.02e-06	2.6e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—ocular cancer	6.98e-06	2.59e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—ocular cancer	6.95e-06	2.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—ocular cancer	6.77e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—ocular cancer	6.77e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—ocular cancer	6.77e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—ocular cancer	6.75e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—ocular cancer	6.75e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—ocular cancer	6.75e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—ocular cancer	6.71e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—ocular cancer	6.71e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—ocular cancer	6.71e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—ocular cancer	6.68e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—ocular cancer	6.66e-06	2.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—ocular cancer	6.61e-06	2.45e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNA11—ocular cancer	6.53e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—ocular cancer	6.29e-06	2.33e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—ocular cancer	6.2e-06	2.3e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—ocular cancer	6.17e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—ocular cancer	6.14e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNAQ—ocular cancer	6.07e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	5.73e-06	2.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—ocular cancer	5.62e-06	2.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—ocular cancer	5.62e-06	2.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—ocular cancer	5.62e-06	2.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—ocular cancer	5.56e-06	2.06e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—ocular cancer	5.56e-06	2.06e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—ocular cancer	5.56e-06	2.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—ocular cancer	5.54e-06	2.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—ocular cancer	5.48e-06	2.03e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—ocular cancer	5.32e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—ocular cancer	5.32e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—ocular cancer	5.32e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—ocular cancer	5.24e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNA11—ocular cancer	5.04e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	4.9e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—ocular cancer	4.86e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—ocular cancer	4.7e-06	1.74e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—ocular cancer	4.7e-06	1.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—ocular cancer	4.7e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNAQ—ocular cancer	4.69e-06	1.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—ocular cancer	4.63e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—ocular cancer	3.42e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—ocular cancer	3.14e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—ocular cancer	2.94e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—ocular cancer	2.8e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—ocular cancer	2.58e-06	9.55e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—ocular cancer	2.55e-06	9.47e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—ocular cancer	2.18e-06	8.09e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—ocular cancer	2.07e-06	7.67e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—ocular cancer	1.9e-06	7.03e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—ocular cancer	1.69e-06	6.28e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—ocular cancer	1.68e-06	6.25e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—ocular cancer	1.56e-06	5.77e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—ocular cancer	1.54e-06	5.72e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—ocular cancer	1.32e-06	4.89e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—ocular cancer	1.02e-06	3.78e-06	CbGpPWpGaD
